IQVIA Holdings (IQV) Peer Comparison
$263.53
$5.09
(1.97%)
As on 03-Nov-2026 13:44EST
Market cap
$44,890 Mln
Revenue (TTM)
$17,311 Mln
P/E Ratio
33.1
P/B Ratio
6.8
Div. Yield
0 %
Edit
| IQVIA Holdings (IQV) | Regeneron Pharmaceuticals (REGN) | Alnylam Pharmaceuticals (ALNY) | Insmed Inc (INSM) | Medpace Holdings (MEDP) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
44,890 | 95,531 | 22,100 | 24,698 | 18,238 |
Revenue ($ Mln) |
17,311 | 16,896 | 5,013 | 1,520 | 2,838 |
Net Profit ($ Mln) |
1,394.00 | 4,817.40 | 2,724.24 | -605.61 | 517.83 |
Net Margin (%) |
8.05 | 28.51 | 54.34 | -39.85 | 18.24 |
RoE (%) |
21.57 | 14.84 | 116.44 | -84.64 | 87.53 |
Price to Earnings |
33.14 | 23.24 | 8.33 | -- | 36.20 |
Price-To-Book |
6.81 | 2.87 | 6.13 | 34.01 | 31.17 |
Income Statement ($ Mln)
| IQVIA Holdings (IQV) | Regeneron Pharmaceuticals (REGN) | Alnylam Pharmaceuticals (ALNY) | Insmed Inc (INSM) | Medpace Holdings (MEDP) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
17,311.00 | 16,896.20 | 5,013.24 | 1,519.72 | 2,838.39 |
|
Cost of Revenue
|
12,731.00 | 2,404.10 | 1,138.86 | 239.15 | 2,011.22 |
|
Gross Profit
|
5,430.00 | 12,242.20 | 3,036.77 | 481.55 | 760.62 |
|
Operating Expenses
|
2,256.00 | 9,500.60 | 2,896.79 | 1,821.48 | 220.03 |
|
Operating Profit (EBIT)
|
2,324.00 | 4,991.50 | 977.59 | -540.91 | 607.14 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
1,629.00 | 5,686.80 | 856.41 | -598.06 | 626.99 |
|
Provision for Tax
|
253.00 | 869.40 | -1,899.16 | 7.55 | 109.17 |
|
Profit after Tax (Net Income)
|
1,394.00 | 4,817.40 | 2,724.24 | -605.61 | 517.83 |
|
Minority Interest
|
-5.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
514.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| IQVIA Holdings (IQV) | Regeneron Pharmaceuticals (REGN) | Alnylam Pharmaceuticals (ALNY) | Insmed Inc (INSM) | Medpace Holdings (MEDP) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
6,660.00 | 33,498.50 | 3,603.85 | 726.21 | 584.94 |
|
Minority Interest
|
-5.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
15,906.00 | 4,704.60 | 2,327.81 | 903.27 | 221.56 |
|
Current Liabilities
|
7,777.00 | 6,202.10 | 2,063.01 | 596.58 | 1,496.10 |
|
Total Liabilities
|
29,944.00 | 40,558.70 | 4,966.33 | 2,264.56 | 1,975.47 |
Assets ($ Mln)
| IQVIA Holdings (IQV) | Regeneron Pharmaceuticals (REGN) | Alnylam Pharmaceuticals (ALNY) | Insmed Inc (INSM) | Medpace Holdings (MEDP) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
24,023.00 | 23,610.10 | 2,882.01 | 519.55 | 1,057.60 |
|
Current Assets
|
6,451.00 | 20,795.10 | 5,112.66 | 1,706.51 | 1,245.00 |
|
Total Assets
|
29,944.00 | 40,558.70 | 4,966.33 | 2,264.56 | 1,975.47 |
|
Total Debt*
|
16,314.00 | 2,707.00 | 1,261.99 | 741.17 | 146.04 |
|
Net Current Assets
|
-1,326.00 | 0.00 | 3,049.66 | 1,109.93 | -251.10 |
Cashflow ($ Mln)
| IQVIA Holdings (IQV) | Regeneron Pharmaceuticals (REGN) | Alnylam Pharmaceuticals (ALNY) | Insmed Inc (INSM) | Medpace Holdings (MEDP) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
2,654.00 | 4,978.90 | 524.08 | -935.01 | 713.22 |
|
Cash Flow from Investing Activities
|
-2,305.00 | -629.10 | 436.33 | -64.58 | -31.14 |
|
Cash from Financing Activities
|
-150.00 | -3,715.40 | -305.19 | 954.07 | -860.39 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| IQVIA Holdings (IQV) | Regeneron Pharmaceuticals (REGN) | Alnylam Pharmaceuticals (ALNY) | Insmed Inc (INSM) | Medpace Holdings (MEDP) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
6.34 | 13.65 | 18.29 | -82.20 | 57.43 |
|
ROE (%)
|
21.57 | 14.84 | 116.44 | -84.64 | 87.53 |
|
ROA (%)
|
3.69 | 8.78 | 33.09 | -21.63 | 15.15 |
|
EBIT Margin (%)
|
13.74 | 33.93 | 23.79 | -34.09 | 21.70 |
|
Net Margin (%)
|
8.05 | 28.51 | 54.34 | -39.85 | 18.24 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| IQVIA Holdings (IQV) | Regeneron Pharmaceuticals (REGN) | Alnylam Pharmaceuticals (ALNY) | Insmed Inc (INSM) | Medpace Holdings (MEDP) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
8.85 | 18.59 | 56.17 | 239.97 | 20.35 |
|
EBIT Growth (%)
|
3.21 | 10.53 | 815.27 | 52.94 | 18.61 |
|
Net Profit Growth (%)
|
8.65 | 5.23 | 6,153.27 | 48.84 | 19.59 |
|
EPS Growth (%)
|
12.82 | 8.23 | 8,782.16 | 54.46 | 28.06 |
|
Book Value Growth (%)
|
11.16 | 9.85 | 1,433.08 | -25.78 | 108.60 |
Valuation Ratios
| IQVIA Holdings (IQV) | Regeneron Pharmaceuticals (REGN) | Alnylam Pharmaceuticals (ALNY) | Insmed Inc (INSM) | Medpace Holdings (MEDP) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
28.49 | 18.42 | 172.73 | -29.12 | 36.06 |
|
Price / Book Value
|
5.96 | 2.65 | 68.67 | 50.31 | 35.44 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
17.96 | 13.25 | 83.24 | -31.17 | 27.88 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| IQVIA Holdings (IQV) | Regeneron Pharmaceuticals (REGN) | Alnylam Pharmaceuticals (ALNY) | Insmed Inc (INSM) | Medpace Holdings (MEDP) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
2.23 | 0.00 | 0.18 | 0.75 | 0.00 |
|
Short term debt to equity ratio
|
0.19 | 0.02 | 0.11 | 0.03 | 0.00 |
|
Current Ratio
|
0.83 | 3.35 | 2.48 | 2.86 | 0.83 |
|
Quick Ratio
|
0.83 | 2.89 | 2.43 | 2.59 | 0.83 |
|
Interest Coverage
|
3.08 | 122.77 | 3.35 | -6.35 | -- |
Operating Efficiency Ratios
| IQVIA Holdings (IQV) | Regeneron Pharmaceuticals (REGN) | Alnylam Pharmaceuticals (ALNY) | Insmed Inc (INSM) | Medpace Holdings (MEDP) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
19.25 | 44.85 | 21.64 | 17.06 | 15.77 |
|
Asset Turnover
|
0.46 | 0.31 | 0.61 | 0.54 | 0.83 |
|
Receivable days
|
74.65 | 152.19 | 58.17 | 58.08 | 50.42 |
|
Inventory Days
|
-- | 546.66 | 43.48 | 337.31 | -- |
|
Payable days
|
75.32 | 150.27 | 55.05 | 223.67 | 6.26 |
|
Cash Conversion Cycle
|
-- | 548.59 | 46.59 | 171.72 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
